Therapeutic peptide vaccine component targeting IDO1, designed to induce IDO1-specific cytotoxic and helper T-cell responses.
Synthetic IDO1-derived peptide vaccine that induces IDO1-specific CD8+ cytotoxic and CD4+ helper T-cell responses. Activated T cells target and eliminate IDO1-expressing tumor and immunosuppressive cells, reducing tryptophan–kynurenine–mediated immune suppression and enhancing antitumor immunity.
YES
INDIRECT
Vaccine induces IDO1-specific CD8+ T cells (with CD4+ help) that recognize IDO1 peptides on MHC and kill IDO1-expressing cells via T-cell cytotoxicity (perforin/granzyme/Fas).
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
YES
DIRECT
ATLG contains antibodies that bind CD2 on T cells, triggering complement-dependent lysis and Fc-mediated ADCC; crosslinking can also induce apoptosis, depleting CD2+ cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
YES
DIRECT
ATLG antibodies bind CD3ε on T cells and deplete them via complement-dependent cytotoxicity and Fc-mediated ADCC; binding can also induce apoptosis.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
YES
DIRECT
ATLG antibodies bind TCRα/TCR complex on T cells and induce complement-dependent cytotoxicity and Fc-mediated ADCC, leading to lysis and apoptosis of the T cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
YES
DIRECT
ATLG antibodies bind TCRβ on T cells, opsonizing them for complement-dependent lysis and Fc-mediated ADCC, and can also induce apoptosis, leading to direct T-cell depletion.